Eur Rev Med Pharmacol Sci 2021; 25 (3): 1564-1573

DOI: 10.26355/eurrev_202102_24865

Zoledronic acid and fracture risk: a meta-analysis of 12 randomized controlled trials

B. He, J.-Q. Zhao, M.-Z. Zhang, Z.-X. Quan

Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.quanzx18@126.com

 


OBJECTIVE: Zoledronic acid is widely used in patients with osteoporosis, and this meta-analysis aims to explore the influence of zoledronic acid on fracture risk and mortality in patients with osteoporosis or osteopenia.

MATERIALS AND METHODS: We searched PubMed, Google Scholar, and Cochrane Library for randomized clinical trials comparing zoledronic acid with control intervention (i.e., placebo or nothing) for osteoporosis or osteopenia. The fracture and mortality were estimated using the random-effect model.

RESULTS: 12 randomized trials were included in this meta-analysis. Compared to control intervention, zoledronic acid was associated with significantly reduced incidence of fracture at the follow-up of 12 months, 24 months, 36 months and 72 months. In addition, zoledronic acid could remarkably reduce mortality at 12 months and 24 months than control intervention but revealed no influence on mortality at 36 months or 72 months. In terms of adverse events, zoledronic acid might result in the increase in serious atrial fibrillation and death from stroke than control intervention.

CONCLUSIONS: Zoledronic acid is beneficial to reduce the incidence of fracture, while its benefits to reduce the mortality are only observed at the follow-up time of 24 months.

 

Free PDF Download

To cite this article

B. He, J.-Q. Zhao, M.-Z. Zhang, Z.-X. Quan
Zoledronic acid and fracture risk: a meta-analysis of 12 randomized controlled trials

Eur Rev Med Pharmacol Sci
Year: 2021
Vol. 25 - N. 3
Pages: 1564-1573
DOI: 10.26355/eurrev_202102_24865